Stakeholders in Pharmaceutical Policy Development

Author:

Ishaq Geer Mohammad

Abstract

Pharmaceutical policy development is a linear and step-wise process that moves from problem statement or agenda setting, to planning and analysis, to definitions and objectives, to policy formulation and statutory approval, to implementation and monitoring, to policy review and evaluation and finally to improvisation. In the process of developing and implementing such a policy framework several stakeholders including national and multi-national drug manufacturers, state and central governments (including all ministries like health, commerce, trade, industry), regulatory authorities, patients, doctors, pharmacists, pharmaceutical traders, insurance agencies, academia, professional associations, NGOs, civil society and consumer groups assume primary importance without whose active involvement the whole process would be inadequate and sometimes even inappropriate leaving huge gaps in their comprehensiveness, inclusiveness and acceptability. This chapter defines the role and describes the importance of these very stakeholders in the process of pharmaceutical policy development and implementation in any settings across the world.

Publisher

IntechOpen

Reference37 articles.

1. WHO. How to Develop and Implement a National Drug Policy. Second ed. Geneva: World Health Organization, WHO; 2001. p. 4

2. Chan J. A Tool for the Public Policy Process & Stakeholder Engagement: Using co-design methodologies and principles, how might we support policy makers and policy influencers to adopt a user-centered approach to the public policy process and build rapport between stakeholders? [Masters dissertation] submitted to OCAD University in partial fulfillment of the requirements for the degree of Masters of Design in Strategic Foresight and Innovation. Toronto, Ontario, Canada. 2016

3. Chadha A. Reguatory Issues in the Indian Pharmaceutical Industry. 2008. Available from: http://shodhganga.inflibnet.ac.in/bitstream/10603/114212/6/chapter-5.pdf. [Accessed: April 26, 2022]

4. WHO. World Medicines Situation Report 2011. 3rd ed. Available from: http://apps.who.int/medicinedocs/documents/s20054en/s20054en.pdf. [Accessed: April 26, 2022]

5. Light DW, Lexchin J. Foreign free riders and the high price of US medicines. BMJ. 2005;331:958-960

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3